Meningitis can be a frightening diagnosis. Our expert guide breaks down the different types—bacterial, viral, and fungal—and ...

The global meningitis treatment market is estimated to be valued at USD 158.8 million in 2025 and is projected to reach USD 226.2 million by 2035, registering a CAGR of 3.6% over the forecast period.

A press release from the Medical Research Council-The Gambia at the London School of Hygiene and Tropical Medicine (MRCG at LSHTM) on Tuesday, June 24, 2025, stated that the World Health Organisation ...

Thereby ensuring Africa's vaccine self-sufficiency and that the continent is positioned to serve African children ...

MSD – known as Merck & Co in the US and Canada – has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its adult-specific pneumococcal vaccine Capvaxive. The ...

This vaccine helps protect against pneumococcal disease, including, pneumococcal pneumonia, bloodstream infection (bacteremia), and infection of the lining of the brain and spinal cord (meningitis).

The vaccine, marketed under the brand name Capvaxive, has been authorised to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 years and older. Invasive ...

This vaccine protects against pneumococcal infections, which are especially dangerous in children younger than 5 years old. The Centers for Disease Control and Prevention (CDC) recommends that all ...

Understand the importance of the pneumococcal vaccine for adults, children, and anyone with a chronic illness - along with its side effects.

Pneumococcal vaccine is also advised for those who are 65 years old or older and those who have a chronic disease.

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults ...